||WAY-252623 (LXR-623) is an orally bioavailable and highly specifical synthetic modulator of LXR.
||SR9243, an LXR inverse agonist, can induce LXR-corepressor interaction; shows anticancer activity and selectively targets the lipogenesis and Warburg effect.
||BMS-779788 is an LXRα/β partial agonist (IC50: 68/14 nM).
||GW3965 HCl is an effective and specific LXR agonist for hLXRα/β (EC50: 190/30 nM).
||T0901317 is a potent and selective agonist for both LXR and FXR, with EC50 of ~50 nM and 5 μM, respectively; it inhibits nuclear factor/κB (NF/κB).
||AZ876 is a potent, highly selective LXR agonist with Ki/EC50 of 7/6 nM and 11/73 nM for hLXRα and hLXRβ respectively.
||RGX-104 is a liver X receptor (LXR) agonist with potential immunomodulating and antineoplastic activities. It modulates innate immunity via transcriptional activation of the ApoE g
||Gymnemagenin is a potent and selective antagonist for the β isoform of LXR, it has antihyperglycemic activity.
||RGX-104 free Acid
||RGX-104 free Acid is an agonist of potent liver-X nuclear hormone receptor (LXR)
||27-Hydroxycholesterol is a selective modulator of estrogen receptor and an agonist of the liver X receptor.
||Licochalcone E is a potential LXRβ agonist.
||Gymnestrogenin has a dual LXRα±/α² antagonistic profile.
||XL041 (BMS-852927) is an agonist of LXRβ-selective.
||GSK2033 is an antagonist of LXR (pIC50s: 7 and 7.4 for LXRα or LXRβ, respectively).
||Nemorexant is an effective orexin receptor antagonist. It also has IC50s of 2 nM and 3 nM for the Ox1 receptor and Ox2 receptor, respectively.
||Rovazolac is a liver x receptor modulator.
||SR9238 is a synthetic agonist of liver X receptor inverse (IC50s: 214 nM and 43 nM for LXRα and LXRβ, respectively).
||Ethyl 2,4,6-trihydroxybenzoate is a dual-LXR modulator that regulates the expression of key genes in cholesterol homeostasis in multiple cells without inducing lipid accumulation i